Core Insights - Deep Longevity, Inc. has appointed Dylan Kay as Chief Business Officer and Luke Shaffer as Vice President of Sales for the United States, effective January 1, 2026, marking its entry into the U.S. health market [1] - The company plans to launch its commercial operations in the first quarter of 2026, focusing on four key areas: corporate health and wellness programs, health insurance and risk-bearing entities, diagnostic laboratories and longevity clinics, and high-end consumer health platforms [1] - Deep Longevity aims to sign over 50 U.S. corporate clients by the end of 2026, positioning its aging clock technology at the center of the preventive healthcare revolution [2] Company Strategy - The appointments of Kay and Shaffer are strategic moves to leverage their extensive experience in health technology and corporate partnerships to drive growth [1][2] - Deep Longevity's clinically validated aging clocks, including BloodAge, EpigeneticAge, MindAge, BiometricAge, and the upcoming FaceAge, provide actionable insights across molecular, physiological, cognitive, and psychological aging dimensions [1] - The company's SaaS solutions enable employers and insurance companies to transition from passive disease care to proactive, quantifiable personalized longevity programs that can extend healthy lifespan and reduce long-term costs [1] Market Context - The U.S. healthcare expenditure is approximately $4.5 trillion annually, with 90% attributed to chronic diseases, highlighting the significant market opportunity for Deep Longevity's solutions [2] - The leadership of Kay and Shaffer is expected to transform emerging science into enterprise-level impact, aligning with the growing focus on preventive healthcare [2]